PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable[1]ultra-long-acting β2 adrenoreceptor agonist[2] (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer.[3] It utilizes a sulfonamideagonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically mediated adverse events.[4] Its in vivo duration on action confirmed its potential for once-daily use in humans. [5]
The investigation and development of PF-610355 were discontinued in 2011,[6] likely for strategic and regulatory reasons.[7]
^Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, et al. (September 2010). "Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup". Journal of Medicinal Chemistry. 53 (18): 6640–52. doi:10.1021/jm1005989. PMID20804199.
^Acton QA, ed. (2012-01-09). Issues in Medical Chemistry Edition. ScholarlyEditions. ISBN978-1-464-96440-4.
^Cazzola M, Page CP, Rogliani P, Matera MG (April 2013). "β2-agonist therapy in lung disease". American Journal of Respiratory and Critical Care Medicine. 187 (7): 690–6. doi:10.1164/rccm.201209-1739PP. PMID23348973.
